Table 2.
Mean E2 Level During the Trial and Change in E2 Level From Baseline Among Total Sample and Participants in HT Group by Time Since Menopause Stratum
| Variable | Early Postmenopause (<6 y) | Late Postmenopause (≥10 y) | P Value |
|---|---|---|---|
| Total Cohort | |||
| N = 248 | N = 348 | ||
| Mean E2 level during the trial, pg/mL | 29.7 ± 31.8 | 25.5 ± 22.5 | 0.06 |
| Change of E2 level from baseline, pg/mL | 21.7 ± 31.6 | 17.0 ± 22.7 | 0.03 |
| Participants in HT Group | |||
|---|---|---|---|
| N = 125 | N = 172 | ||
| Mean E2 level during the trial, pg/mL | 48.2 ± 35.8 | 40.2 ± 23.6 | 0.02 |
| Change of E2 level from baseline, pg/mL | 40.4 ± 35.4 | 31.6 ± 24.0 | 0.01 |
| Participants in Placebo Group | |||
|---|---|---|---|
| N = 123 | N = 176 | ||
| Mean E2 level during the trial, pg/mL | 10.9 ± 5.9 | 11.0 ± 6.0 | 0.85 |
| Change of E2 level from baseline, pg/mL | 2.8 ± 5.9 | 2.6 ± 6.8 | 0.88 |
Continuous variables: mean ± SD and P value from t test. Among total cohort, test for interaction of treatment * menopausal strata adjusting for baseline E2 level P value = 0.02.